Mon, Sep 29, 2025
Effective Jan. 1, 2026, Highmark is designating additional drugs as voluntary for the Medical Injectable Drug Program.
Highmark continually evaluates the program and makes changes as appropriate. When drugs are added as voluntary, this means physicians may choose to purchase and bill Highmark directly for those drugs and will receive reimbursement as outlined in the program.
Please use Availity Essentials® to access the proposed rate on the effective date for each drug listed below:
HCPCs |
Drug Name |
Q5153 |
Opuviz |
Q5147 |
Pavblu |
Q5149 |
Enzeevu |
Q5150 |
Ahzantive |
Q5135 |
Tyenne IV and SC |
Q5098 |
Imuldosa IV and SC |
Q5099 |
Steqeyma IV and SC |
Q5100 |
Yesintek IV and SC |
Q5137 |
Wezlana SC |
Q5138 |
Wezlana IV |
Q9996 |
Pyzchiva SC |
Q9997 |
Pyzchiva IV |
Q9998 |
Selarsdi IV and SC |
Q9999 |
Otulfi IV and SC |
Q5133 |
Tofidence |
J1299* |
Soliris |
Q5151 |
Epysqli |
Q5152 |
Bkemv |
Q5134 |
Tyruko |
*Applicable Site of Care (SOC) rates apply only to Home Infusion Therapy (HIT) and Ambulatory Infusion Suites (AIS) providers.
Once you log into Availity, select Claims & Payments from the task bar and then Fee Schedule Listing from the right side. You can also access fee schedules by going to Payer Spaces in Availity, and then select Provider Resource Center (PRC) under Applications. Once you arrive at the PRC, choose Claims & Authorization and then click Fee Schedule Information.
Quick Info
Never miss out on what matters. Subscribe to our emails and stay informed.